Raising awareness on women s rights » Borneo Bulletin Online borneobulletin.com.bn - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from borneobulletin.com.bn Daily Mail and Mail on Sunday newspapers.
Tuesday, April 6, 2021
It’s the conundrum that Line of Duty viewers have been wrestling with for a long time. Who is the mysterious H ?
Some viewers reckon that the question may have been answered in the latest episode, with a theory spreading on Twitter that the corrupt figure is actually PCC Rohan Sindwhani.
Why Sindwhani? Well, fans of the hit BBC show will have noticed that in Sunday’s episode (S6, E3) he was clearly annoyed with Ted Hastings’ continued pursuit of H . During one of their typically tense exchanges, he also berates Hastings over AC-12 s arrests of DCI Jo Davidson and Farida Jatria, and he complains that, I ve had to call in favours from half a dozen editors to keep this out of the press.
Oxurion NV Business and Financial Update finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
First patients dosed in Phase 2 study (‘KALAHARI’) evaluating multiple injections of THR-149, a potent plasma kallikrein inhibitor, for the treatment of DME. Part A data expected by mid-year
THR-687, a pan-RGD integrin antagonist, Phase 2 DME study planned to start by mid-year, following positive Phase 1 data released in 2020
The Company has strengthened the management team with the appointments of Tom Graney, CFA, based in Boston as CFO, Grace Chang M.D., PhD, based in LA as CMO, and Professor Alan Stitt, PhD as CSO.
At the end of December 2020, Oxurion had cash, cash equivalents & investments of €24.8 million, allowing the Company to execute on its business plans through the end of Q3 2021. The Company is in advanced discussions with potential investors in order to increase its cash position.
First patients dosed in Phase 2 study (‘KALAHARI’) evaluating multiple injections of THR-149, a potent plasma kallikrein inhibitor, for the treatment of DME. Part A data expected by mid-year
THR-687, a pan-RGD integrin antagonist, Phase 2 DME study planned to start by mid-year, following positive Phase 1 data released in 2020
The Company has strengthened the management team with the appointments of Tom Graney, CFA, based in Boston as CFO, Grace Chang M.D., PhD, based in LA as CMO, and Professor Alan Stitt, PhD as CSO.
At the end of December 2020, Oxurion had cash, cash equivalents & investments of €24.8 million, allowing the Company to execute on its business plans through the end of Q3 2021. The Company is in advanced discussions with potential investors in order to increase its cash position.